Gastric Cancer Market: HER2+ Segment Valued at USD 700 Million in 2024 Across the 7MM | DelveInsight

DelveInsight's "Gastric Cancer Market Insight, Epidemiology and Market Forecast - 2034" report delivers an in-depth analysis of gastric cancer epidemiology, market, and clinical development in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Explore the intricate details of the Gastric Cancer Market Report @ https://www.delveinsight.com/report-store/gastric-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from Gastric Cancer Market Report
• Gastric cancer represents the fifth most prevalent malignant tumor, with the highest incidence rates observed in Eastern Asia and Eastern Europe.
• Japan had the highest number of incident cases of gastric cancer among the 7MM in 2024, with around 129,500 cases.
• The total number of incident cases of gastric cancer (including GEJ) in the 7MM accounted for approximately 211,550 in 2024, and these cases are expected to increase by 2034.
• Around 37% of cases are diagnosed in distant stages of gastric cancer in the US, while in Japan, the majority of cases are diagnosed at an early stage (Stage I).
• Metastatic disease is present in about 35% of patients in the United States at the time of diagnosis.
• Gastric cancer is 2.2 times more likely to be diagnosed in males than females.
• The average age at diagnosis is 68, and about 6 of every 10 people diagnosed each year are 65 or older.
• The total market size of HER2+ gastric cancer (including GEJ) in the 7MM was approximately USD 700 million in 2024, with Germany accounting for the maximum market size among EU4 countries and the United Kingdom at the bottom of the ladder.
• Trastuzumab ± Chemotherapy generated the largest revenue among current HER2+ gastric cancer therapies in the United States in 2024, at roughly USD 140 million.
• ENHERTU is expected to generate the highest revenue among all emerging therapies in the EU4 and the UK by 2034.
• Approved Gastric Cancer Companies include AstraZeneca, Daiichi Sankyo, Bristol-Myers Squibb, Merck, Blueprint Medicines, Genentech, Astellas Pharma, BeOne Medicines (BeiGene), and others.
• Promising Gastric Cancer Therapies include Bemarituzumab, ZIIHERA (zanidatamab), Rilvegostomig, AZD0901, Evorpacept, TUKYSA, A166, ELVN-002, ARX788, and others.

Get a Free sample for the Gastric Cancer Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/gastric-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

What is Gastric Cancer?
Gastric (stomach) cancer occurs when cancer cells form in the stomach's lining. The stomach wall has five layers: mucosa, submucosal, muscularis propria, subserosa, and serosa. The location of the tumor and the layers involved play an important role in determining the stage of cancer, which affects treatment options and prognosis. As cancer grows from the mucosa into deeper layers, the stage becomes more advanced and demands more extensive treatment. To diagnose gastric cancer, doctors may review personal and family medical history, perform a physical exam, and run blood and stool tests for signs of anemia or bleeding. Key diagnostic procedures include upper endoscopy with biopsy and barium swallow x-rays, while advanced imaging such as CT scans, endoscopic ultrasound, PET-CT scans, and MRI help stage the cancer and guide treatment decisions.

Gastric Cancer Epidemiology Segmentation in the 7MM
• Total Incident Cases of Gastric Cancer
• Stage-specific Cases of Gastric Cancer
• Gender-specific Cases of Gastric Cancer
• Biomarker-specific Cases of Gastric Cancer
• Total Treatable Cases of Gastric Cancer

Download the report to understand which factors are driving Gastric Cancer epidemiology trends @ https://www.delveinsight.com/report-store/gastric-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Gastric Cancer Approved Therapies
• ENHERTU (Fam-Trastuzumab Deruxtecan-nxki): AstraZeneca/Daiichi Sankyo
ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate approved for adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction adenocarcinoma who have previously received a trastuzumab-based regimen, in addition to other solid tumors. It received FDA approval in the US in 2021, European Commission approval in 2022, and FDA Breakthrough Therapy designation in 2020. In April 2024, ENHERTU was approved in the US as the first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors.

• OPDIVO (nivolumab): Bristol-Myers Squibb
OPDIVO is used in combination with fluoropyrimidine- and platinum-containing chemotherapy to treat adults with gastric, gastroesophageal junction, and esophageal adenocarcinoma that cannot be removed with surgery or has spread. In May 2021, the FDA approved OPDIVO as an adjuvant treatment for patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease following neoadjuvant chemoradiotherapy, based on Phase III CHECKMATE-577 data.

Other approved therapies include KEYTRUDA (Merck), CYRAMZA (Eli Lilly), AYVAKIT (Blueprint Medicines), HERCEPTIN (Genentech), VYLOY (Astellas Pharma), and TEVIMBRA (BeOne Medicines/BeiGene). In December 2024, the US FDA approved TEVIMBRA in combination with platinum and fluoropyrimidine-based chemotherapy for the 1L treatment of unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma in adults whose tumors express PD-L1 (≥1). In March 2024, Japan's MHLW approved VYLOY (zolbetuximab), the first CLDN18.2-targeted therapy approved by any regulatory agency worldwide.

Gastric Cancer Pipeline Analysis
• Bemarituzumab: Amgen
Bemarituzumab is a monoclonal antibody inhibiting fibroblast growth factor receptor 2b (FGFR2b), under investigation for advanced gastric and GEJ cancers. It received FDA Breakthrough Therapy designation in April 2021. Results from the Phase III FORTITUDE-101 (first-line gastric cancer) and FORTITUDE-102 trials were anticipated in 2025.

• ZIIHERA (zanidatamab): Jazz Pharmaceuticals, BeiGene, and Zymeworks
ZIIHERA is a bispecific HER2-directed antibody binding two extracellular sites on HER2. It received FDA accelerated approval in November 2024 for previously treated HER2+ biliary tract cancer and is currently in Phase III trials for HER2+ unresectable locally advanced or metastatic gastroesophageal adenocarcinoma. Jazz Pharmaceuticals anticipated a top-line data readout from the pivotal Phase III HERIZON-GEA-01 trial in Q2 2025, with a potential sBLA submission in 2025 and possible approval and launch as a first-line GEA treatment in 2026.

Other pipeline candidates include Rilvegostomig and AZD0901 (AstraZeneca), Evorpacept (ALX Oncology), TUKYSA (Pfizer), A166 (KLUS Pharma), ELVN-002 (Enliven Therapeutics), and ARX788 (Ambrx and NovoCodex).

Gastric Cancer Companies
AstraZeneca, Daiichi Sankyo, Bristol-Myers Squibb, Merck, Blueprint Medicines, Genentech, Astellas Pharma, BeOne Medicines (BeiGene), Jazz Pharmaceuticals, Zymeworks, ALX Oncology, Pfizer, Amgen, Enliven Therapeutics, Ambrx and NovoCodex, KLUS Pharma, and others.

Discover more about therapies set to grab major Gastric Cancer market share @ https://www.delveinsight.com/sample-request/gastric-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Gastric Cancer Market Outlook
The gastric cancer treatment market is expected to grow, supported by advances in targeted therapies and immunotherapies. Platinum-based chemotherapy and gastrectomy remain important treatment approaches, while HER2-directed therapies such as ENHERTU continue expanding options for HER2-positive advanced disease. OPDIVO has strengthened its role in esophageal and GEJ cancers. Emerging targets, including FGFR2b and CLDN18.2, are gaining attention, with bemarituzumab and zolbetuximab demonstrating therapeutic potential. At ASCO 2025, ENHERTU showed improved overall survival, response rates, disease control, and progression-free survival versus ramucirumab plus paclitaxel. Pipeline developments, including SIGX1094 and evorpacept, further highlight continued innovation across gastric cancer treatment.

Scope of the Gastric Cancer Market Report
• Study Period: 2020-2034
• Forecast Period: 2025-2034
• Geographies Covered: US, EU4 (Germany, France, Italy, and Spain), UK, and Japan
• Gastric Cancer Companies: AstraZeneca, Daiichi Sankyo, Bristol-Myers Squibb, Merck, Blueprint Medicines, Genentech, Astellas Pharma, BeOne Medicines (BeiGene), and others
• Gastric Cancer Therapies: ENHERTU, OPDIVO, KEYTRUDA, AYVAKIT, HERCEPTIN, VYLOY, TEVIMBRA, ZIIHERA, and others
• Gastric Cancer Therapeutic Assessment: Current marketed and emerging therapies
• Gastric Cancer Market Dynamics: Market drivers and market barriers
• Analysis: KOL Views, SWOT Analysis, Reimbursement, Conjoint Analysis, Analyst Views, Unmet Needs

To know more about Gastric Cancer companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/gastric-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
5. Epidemiology and Market Methodology
6. Gastric Cancer: Market Overview at a Glance
7. Disease Background and Overview: Gastric Cancer
8. Treatment and Guidelines
9. Epidemiology and Patient Population
10. Patient Journey
11. Marketed Drugs
12. Emerging Therapies
13. Gastric Cancer: Market Size
14. Unmet Needs
15. SWOT Analysis
16. KOL Views
17. Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.